OBJECTIVE:Cancer-related fatigue (CRF) is one of the most common, persistent, and disabling symptoms associated with cancer and its treatment. Evidence-based treatments that are acceptable to patients are critically needed. This study examined the efficacy of mindfulness-based stress reduction (MBSR) for CRF and related symptoms. METHOD: A sample of 35 cancer survivors with clinically significant CRF was randomly assigned to a 7-week MBSR-based intervention or wait-list control group. The intervention group received training in mindfulness meditation, yoga, and self-regulatory responses to stress. Fatigue interference (primary outcome) and a variety of secondary outcomes (e.g., fatigue severity, vitality, disability, depression, anxiety, and sleep disturbance) were assessed at baseline, post-intervention, and 1-month follow-up. Bonferroni correction was employed to account for multiple comparisons. Controls received the intervention after the 1-month follow-up. Participants in both groups were followed for 6 months after completing their respective MBSR courses to assess maintenance of effects. RESULTS: Compared to controls, the MBSR group reported large post-intervention reductions as assessed by effect sizes (d) in the primary outcome, fatigue interference (d = -1.43, p < 0.001), along with fatigue severity (d = -1.55, p < 0.001), vitality (d = 1.29, p < 0.001), depression (d = -1.30, p < 0.001), and sleep disturbance (d = -0.74, p = 0.001). Results were maintained or strengthened at 1-month follow-up, the point at which significant improvements in disability (d = -1.22, p < 0.002) and anxiety (d = -0.98, p = 0.002) occurred. Improvements in all outcomes were maintained 6 months after completing the course. MBSR adherence was high, with 90% attendance across groups and high rates of participant-reported home practice of mindfulness. CONCLUSIONS:Mindfulness-based stress reduction is a promising treatment for CRF and associated symptoms.
RCT Entities:
OBJECTIVE:Cancer-related fatigue (CRF) is one of the most common, persistent, and disabling symptoms associated with cancer and its treatment. Evidence-based treatments that are acceptable to patients are critically needed. This study examined the efficacy of mindfulness-based stress reduction (MBSR) for CRF and related symptoms. METHOD: A sample of 35 cancer survivors with clinically significant CRF was randomly assigned to a 7-week MBSR-based intervention or wait-list control group. The intervention group received training in mindfulness meditation, yoga, and self-regulatory responses to stress. Fatigue interference (primary outcome) and a variety of secondary outcomes (e.g., fatigue severity, vitality, disability, depression, anxiety, and sleep disturbance) were assessed at baseline, post-intervention, and 1-month follow-up. Bonferroni correction was employed to account for multiple comparisons. Controls received the intervention after the 1-month follow-up. Participants in both groups were followed for 6 months after completing their respective MBSR courses to assess maintenance of effects. RESULTS: Compared to controls, the MBSR group reported large post-intervention reductions as assessed by effect sizes (d) in the primary outcome, fatigue interference (d = -1.43, p < 0.001), along with fatigue severity (d = -1.55, p < 0.001), vitality (d = 1.29, p < 0.001), depression (d = -1.30, p < 0.001), and sleep disturbance (d = -0.74, p = 0.001). Results were maintained or strengthened at 1-month follow-up, the point at which significant improvements in disability (d = -1.22, p < 0.002) and anxiety (d = -0.98, p = 0.002) occurred. Improvements in all outcomes were maintained 6 months after completing the course. MBSR adherence was high, with 90% attendance across groups and high rates of participant-reported home practice of mindfulness. CONCLUSIONS: Mindfulness-based stress reduction is a promising treatment for CRF and associated symptoms.
Authors: Kristine A Donovan; Paul B Jacobsen; Brent J Small; Pamela N Munster; Michael A Andrykowski Journal: J Pain Symptom Manage Date: 2008-05-20 Impact factor: 3.612
Authors: Karen M Mustian; Gary R Morrow; Jennifer K Carroll; Colmar D Figueroa-Moseley; Pascal Jean-Pierre; Geoffrey C Williams Journal: Oncologist Date: 2007
Authors: Susanne M Cutshall; Stephen S Cha; Sheryl M Ness; Daniela L Stan; Sarah A Christensen; Anjali Bhagra; Katharine A Price; Carrie A Thompson; Shahrukh K Hashmi; Tony Y Chon; Tracy J McCray; Amit Sood; Brent A Bauer; Kathryn J Ruddy Journal: Support Care Cancer Date: 2015-02-28 Impact factor: 3.603
Authors: Cecile A Lengacher; Richard R Reich; Carly L Paterson; Sophia Ramesar; Jong Y Park; Carissa Alinat; Versie Johnson-Mallard; Manolete Moscoso; Pinky Budhrani-Shani; Branko Miladinovic; Paul B Jacobsen; Charles E Cox; Matthew Goodman; Kevin E Kip Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Catherine E Mosher; Ekin Secinti; Ruohong Li; Adam T Hirsh; Jonathan Bricker; Kathy D Miller; Bryan Schneider; Anna Maria Storniolo; Lida Mina; Erin V Newton; Victoria L Champion; Shelley A Johns Journal: Support Care Cancer Date: 2018-01-12 Impact factor: 3.603
Authors: Shelley A Johns; Linda F Brown; Kathleen Beck-Coon; Tasneem L Talib; Patrick O Monahan; R Brian Giesler; Yan Tong; Laura Wilhelm; Janet S Carpenter; Diane Von Ah; Christina D Wagner; Mary de Groot; Karen Schmidt; Diane Monceski; Marie Danh; Jennifer M Alyea; Kathy D Miller; Kurt Kroenke Journal: Support Care Cancer Date: 2016-05-17 Impact factor: 3.603
Authors: Po-Ju Lin; Luke J Peppone; Michelle C Janelsins; Supriya G Mohile; Charles S Kamen; Ian R Kleckner; Chunkit Fung; Matthew Asare; Calvin L Cole; Eva Culakova; Karen M Mustian Journal: Curr Oncol Rep Date: 2018-02-01 Impact factor: 5.075